Transient receptor potential vanilloid receptor 1 (TRPV1)-mediated release of neuroactive peptides and neurotransmitters from the peripheral and central terminals of primary sensory neurons can critically contribute to nociceptive processing at the periphery and in the CNS. However, the mechanisms that link TRPV1 activation with Ca 2ϩ signaling at the release sites and neurosecretion are poorly understood. Here we demonstrate that a brief stimulation of the receptor using either capsaicin or the endogenous TRPV1 agonist N-arachidonoyl-dopamine induces a prolonged elevation of presynaptic [Ca 2ϩ ] i and a concomitant enhancement of glutamate release at sensory synapses. Initiation of this response required Ca 2ϩ entry, primarily via TRPV1. The sustained phase of the response was independent of extracellular Ca 2ϩ and was prevented by inhibitors of mitochondrial Ca 2ϩ uptake and release mechanisms. Measurements using a mitochondria-targeted Ca 2ϩ indicator, mtPericam, revealed that TRPV1 activation elicits a long-lasting Ca 2ϩ elevation in presynaptic mitochondria. The concentration of TRPV1 agonist determined the duration of mitochondrial and cytosolic Ca 2ϩ signals in presynaptic boutons and, consequently, the period of enhanced glutamate release and action potential firing by postsynaptic neurons. These data suggest that mitochondria control vanilloid-induced neurotransmission by translating the strength of presynaptic TRPV1 stimulation into duration of the postsynaptic response.Key words: TRPV1; capsaicin; NADA; calcium; mitochondria; DRG neurons
IntroductionThe transient receptor potential vanilloid receptor 1 (TRPV1) is a critical molecular detector of noxious signals in primary sensory neurons. A broad range of pain-producing stimuli either directly activate or modulate TRPV1. This includes noxious heat, protons, lipid-derived endovanilloids, and inflammatory mediators (Caterina and Julius, 2001;De Petrocellis and Di Marzo, 2005). Behavioral studies using TRPV1 knock-out mice or selective TRPV1 antagonists have indicated that the receptor is involved in the development of various chronic pain conditions, including those associated with cancer, arthritis, irritable bowel syndrome, and migraine (Caterina et al., 2000;Davis et al., 2000;Akerman et al., 2004;Ghilardi et al., 2005;Jones et al., 2005;Szabo et al., 2005). Accordingly, TRPV1 presents an attractive target for analgesics, and several TRPV1 antagonists are currently under preclinical investigation or clinical trials (Immke and Gavva, 2006;Szallasi et al., 2007).TRPV1 is a nonselective cation channel with a high Ca 2ϩ permeability, and robust Ca 2ϩ entry into the cell is a hallmark of receptor activation (Caterina et al., 1997). At the peripheral terminals of primary nociceptors, TRPV1-mediated Ca 2ϩ influx triggers the release of neuropeptides, which contributes to the development of neurogenic inflammation (Caterina and Julius, 2001). TRPV1 is also found in the central processes of primary afferent neurons (Guo et al., 1999;Hwang et al., 2004), and...